GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Earnings per Share (Diluted)

LAVA Therapeutics NV (LAVA Therapeutics NV) Earnings per Share (Diluted) : $-1.57 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Earnings per Share (Diluted)?

LAVA Therapeutics NV's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.22. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.57.

LAVA Therapeutics NV's EPS (Basic) for the three months ended in Dec. 2023 was $-0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.57.

LAVA Therapeutics NV's EPS without NRI for the three months ended in Dec. 2023 was $-0.17. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.53.

During the past 3 years, the average EPS without NRIGrowth Rate was -36.00% per year.

During the past 5 years, LAVA Therapeutics NV's highest 3-Year average EPS without NRI Growth Rate was -36.00% per year. The lowest was -36.70% per year. And the median was -36.35% per year.


LAVA Therapeutics NV Earnings per Share (Diluted) Historical Data

The historical data trend for LAVA Therapeutics NV's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Earnings per Share (Diluted) Chart

LAVA Therapeutics NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
-0.53 -0.63 -2.14 -1.23 -1.57

LAVA Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.53 -0.48 -0.34 -0.22

Competitive Comparison of LAVA Therapeutics NV's Earnings per Share (Diluted)

For the Biotechnology subindustry, LAVA Therapeutics NV's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LAVA Therapeutics NV's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's PE Ratio distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's PE Ratio falls into.



LAVA Therapeutics NV Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

LAVA Therapeutics NV's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-41.974-0)/26.733
=-1.57

LAVA Therapeutics NV's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-6.498-0)/28.063
=-0.23

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


LAVA Therapeutics NV  (NAS:LVTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


LAVA Therapeutics NV Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Yalelaan 62, Utrecht, UT, NLD, 3584 CM
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

LAVA Therapeutics NV (LAVA Therapeutics NV) Headlines

From GuruFocus

LAVA Therapeutics Announces Two Appointments to its Board of Directors

By GuruFocusNews GuruFocusNews 07-05-2022

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

By Stock market mentor Stock market mentor 02-06-2023

LAVA Therapeutics Announces Appointment of New Directors to the Board

By Stock market mentor Stock market mentor 01-06-2023